Yatharth Hospital & Trauma Care Services Ltd Valuation Shifts Signal Expensive Territory

Valuation Metrics Reflect Elevated Pricing

As of 12 Feb 2026, Yatharth Hospital’s P/E ratio stands at 39.38, a level that marks a significant premium compared to its own historical valuation and the broader hospital industry. This figure has contributed to the company’s valuation grade being downgraded from fair to expensive, signalling that investors are now paying a higher price for each unit of earnings generated by the company.

The price-to-book value ratio has also climbed to 3.90, further underscoring the premium valuation. This metric indicates that the market values the company at nearly four times its net asset value, a level that is elevated but not uncommon in the hospital sector, where intangible assets and growth prospects often command a premium.

Other valuation multiples such as EV/EBITDA at 24.36 and EV/EBIT at 33.44 reinforce the expensive valuation narrative. These multiples are above typical sector averages, reflecting heightened expectations for operational profitability and cash flow generation.

Comparative Analysis with Peers

When benchmarked against key competitors, Yatharth Hospital’s valuation appears more moderate but still expensive. For instance, Aster DM Healthcare trades at a P/E of 83.74 and EV/EBITDA of 37.08, while Krishna Institute of Medical Sciences commands a P/E of 93.61 and EV/EBITDA of 38.33. Dr Lal Pathlabs, another major player, is classified as very expensive with a P/E of 44.06 and EV/EBITDA of 30.22.

These comparisons suggest that while Yatharth Hospital is expensive, it remains relatively more attractively priced than some of its larger peers. However, the premium over historical valuation and the shift in grading to a sell recommendation by MarketsMOJO’s Mojo Grade (currently 42.0) indicates caution for investors.

Financial Performance and Returns Contextualise Valuation

Yatharth Hospital’s return profile has been robust over the past year, with a stock return of 67.44% compared to the Sensex’s 10.41% over the same period. This outperformance has likely contributed to the re-rating of the stock. However, the year-to-date return is a modest 0.36%, signalling some recent consolidation after strong gains.

The company’s return on capital employed (ROCE) is 12.32%, and return on equity (ROE) stands at 9.03%. These figures, while respectable, do not fully justify the elevated valuation multiples, especially when compared to peers with higher profitability metrics.

Moreover, the absence of a dividend yield may deter income-focused investors, placing greater emphasis on capital appreciation to justify the current price levels.

Market Capitalisation and Price Movement

Yatharth Hospital’s market capitalisation grade is rated 3, indicating a mid-sized market cap within its sector. The stock price closed at ₹684.00 on 12 Feb 2026, up 1.21% from the previous close of ₹675.85. The 52-week trading range spans from ₹345.35 to ₹843.00, reflecting significant volatility and a strong upward trend over the past year.

Intraday price action on the news generation date showed a high of ₹699.95 and a low of ₹672.05, suggesting some profit-taking near the upper end of the recent trading range. This price behaviour aligns with the valuation concerns raised by the shift to an expensive rating.

Sector and Industry Context

The hospital sector continues to attract investor interest due to its defensive characteristics and growth potential driven by rising healthcare demand in India. However, valuations across the sector have generally expanded, with many companies trading at premium multiples reflecting strong earnings growth expectations and structural tailwinds.

Yatharth Hospital’s valuation upgrade to expensive is consistent with this broader sector trend but also highlights the need for investors to carefully assess whether the current price adequately reflects future growth prospects and risks.

Investment Outlook and Rating Implications

MarketsMOJO has downgraded Yatharth Hospital’s Mojo Grade from Hold to Sell as of 06 Feb 2026, signalling a more cautious stance. The current Mojo Score of 42.0 reflects concerns about valuation stretch and the risk of limited upside from current levels.

Investors should weigh the company’s strong recent returns and sector positioning against the elevated multiples and moderate profitability metrics. The PEG ratio of 1.38 suggests that growth expectations are priced in but not excessively so, leaving room for performance to justify the premium if growth accelerates.

Nonetheless, the absence of dividend yield and the relatively modest ROE compared to peers may temper enthusiasm among value-oriented investors.

Conclusion: Valuation Re-rating Demands Caution

Yatharth Hospital & Trauma Care Services Ltd’s transition from fair to expensive valuation territory marks a critical juncture for investors. While the company has delivered impressive returns over the past year and maintains a solid position within the hospital sector, the elevated P/E, P/BV, and EV multiples suggest that much of the anticipated growth is already priced in.

Comparisons with peers reveal that although Yatharth is less expensive than some larger hospital chains, the recent downgrade in its Mojo Grade to Sell reflects heightened risk of valuation correction or limited upside in the near term. Investors should carefully monitor operational performance, sector dynamics, and broader market conditions before committing fresh capital.

In the current environment, a balanced approach that considers both the company’s growth potential and valuation risks is essential for making informed investment decisions.

Unlock special upgrade rates for a limited period. Start Saving Now →